Skip to main content
SpringerLink
Log in

Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

This review summarises the available data on the population pharmacokinetics of tacrolimus and use of Maximum A Posteriori (MAP) Bayesian estimation to predict tacrolimus exposure and subsequent drug dosage requirements in solid organ transplant recipients. A literature search was conducted which identified 56 studies that assessed the population pharmacokinetics of tacrolimus based on non-linear mixed effects modelling and 14 studies that assessed the predictive performance of MAP Bayesian estimation of tacrolimus area under the plasma concentration–time curve (AUC) from time zero to the end of the dosing interval. Studies were most commonly undertaken in adult kidney transplant recipients and investigated the immediate-release formulation. The pharmacokinetics of tacrolimus were described using one- and two-compartment disposition models with first-order elimination in 61 and 39 % of population pharmacokinetic studies, respectively. Variability in tacrolimus whole blood apparent clearance amongst transplant recipients was most commonly related to cytochrome P450 (CYP) 3A5 genotype (rs776746), patient haematocrit, patient weight, post-operative day and hepatic function (aspartate aminotransferase). Bias, as calculated using estimation of the mean predictive error (MPE) or mean percentage predictive error (MPPE) associated with prediction of the tacrolimus AUC, ranged from −15 to 9.95 %. Imprecision, as calculated through estimation of the root mean squared error (RMSE) or mean absolute prediction error (MAPE), was generally much poorer overall, ranging from 0.81 to 40. r 2 values ranged from 0.27 to 0.99 %. Of the Bayesian forecasting strategies that used two or more tacrolimus concentrations, 71 % showed bias of 10 % or less; however, only 39 % showed imprecision of 10 % or less. The combination of sampling times at 0, 1 and 3 h post-dose consistently showed bias and imprecision values of less than 15 %. No studies to date have examined how closely MAP Bayesian dosage predictions of tacrolimus actually achieve target AUC by comparing dosage prediction from one occasion with a future measured AUC. Further research involving larger prospective studies including more diverse transplant groups and the extended-release formulation of tacrolimus is needed. Several questions require further examination, including the following. Do Bayesian forecasting methods currently use the most appropriate population pharmacokinetic models and optimal sampling times for dosage prediction? Does Bayesian forecasting perform well when applied to make dosage predictions on a subsequent occasion? How can Bayesian forecasting be simplified for use in the clinical setting? And, are patient outcomes improved with dosage prediction based on Bayesian forecasting compared with trough concentration monitoring?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Staatz C, Tett SE. Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin Pharmacokinet. 2015;54(10):993–1025.

    Article  CAS  PubMed  Google Scholar 

  2. Hesselink D, van Gelder T, van Schaik R. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualised immunosuppression. Pharmacogenomics. 2005;6(4):323–37.

    Article  CAS  PubMed  Google Scholar 

  3. Staatz C, Tett S. Clinical pharmacokinetics and pharmacodynamis of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623–53.

    Article  CAS  PubMed  Google Scholar 

  4. Shuker N, van Gelder T, Hesselink A. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev. 2015;29(2):78–84.

    Article  Google Scholar 

  5. Scott L, McKeage K, Keam S, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2000;63(12):1247–97.

    Article  Google Scholar 

  6. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced C 0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation. 2010;90(5):523–9.

    Article  PubMed  Google Scholar 

  7. Wallemacq P, Armstrong V, Brrunet M, et al. Opportunities to optimise tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit. 2009;31(2):139–52.

    Article  CAS  PubMed  Google Scholar 

  8. Laskow D, Vincenti F, Neylan J, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation. Transplantation. 1996;62(7):900–5.

    Article  CAS  PubMed  Google Scholar 

  9. Kershner R, Fitzsimmons W. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62(7):920–6.

    Article  CAS  PubMed  Google Scholar 

  10. Saint-Marcoux F, Woillard J, Jurado C, et al. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit. 2013;35(3):322–7.

    Article  CAS  PubMed  Google Scholar 

  11. Venkataramanan R, Shaw L, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41:542–51.

    Article  CAS  PubMed  Google Scholar 

  12. Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1998;48:4445–8.

    Google Scholar 

  13. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905–9.

    Article  CAS  PubMed  Google Scholar 

  14. Undre N, Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296–8.

    Article  CAS  PubMed  Google Scholar 

  15. Daher Abdi Z, Premaud A, Essig M, et al. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. Clin Pharmacol Ther. 2014;96(4):508–15.

    Article  CAS  PubMed  Google Scholar 

  16. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(dagger). Am J Transplant. 2013;13(5):1253–61.

    Article  CAS  PubMed  Google Scholar 

  17. Knoop C, Thiry P, Saint-Marcoux F, et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant. 2005;5(6):1477–82.

    Article  CAS  PubMed  Google Scholar 

  18. Wong K, Shek C, Chau K, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis. 2000;35(4):660–6.

    Article  CAS  PubMed  Google Scholar 

  19. Ting L, Villeneuve E, Ensom M. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28(3):419–30.

    Article  CAS  PubMed  Google Scholar 

  20. van Der meer A, Marcus M, Touw D, et al. Optimal sampling strategy development methodology using Maximum A Posteriori Bayesian estimation. Ther Drug Monit. 2011;33:133–46.

    PubMed  Google Scholar 

  21. Staatz C, Tett S. Maximum A Posteriori Bayesian estimation of mycophenolic acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2011;50(12):759–72.

    Article  CAS  PubMed  Google Scholar 

  22. Beal A, Sheiner LB, Boeckmann A, et al. NONMEM user’s guides (1989–2009). Ellicott City: Icon Development Solutions; 2009.

    Google Scholar 

  23. Storset E, Holford N, Midtvedt K, et al. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70(1):65–77.

    Article  PubMed  CAS  Google Scholar 

  24. Andrews LM, Riva N, de Winter BC, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol. 2015;11(6):921–36.

    Article  CAS  PubMed  Google Scholar 

  25. Woillard J, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations–twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71(3):391–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Musuamba F, Mourad M, Haufroid V, et al. Statistical tools for dose individualisation of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. Br J Clin Pharmacol. 2013;75(5):1277–88.

    Article  CAS  PubMed  Google Scholar 

  27. Musuamba F, Mourad M, Haufroid V, et al. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol. 2012;52(12):1833–43.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang JLS, Xue L, Ding X, Zhang H, Miao L. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2015;53(9):728–36.

    Article  CAS  PubMed  Google Scholar 

  29. Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005;61(5–6):409–16.

    Article  CAS  PubMed  Google Scholar 

  30. Lee J, Hahn H, Son I, et al. Factors affecting the apparent clearance of tacrolimus in korean adult liver transplant recipients. Pharmacotherapy. 2006;26(8):1069–77.

    Article  CAS  PubMed  Google Scholar 

  31. Zhu L, Yang J, Zhang Y, et al. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of tacrolimus in Chinese adult liver transplant patients. Xenobiotica. 2015;45(9):840–6.

    Article  CAS  PubMed  Google Scholar 

  32. Jalil M, Hawwa AF, McKiernan PJ, et al. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Br J Clin Pharmacol. 2014;77(1):130–40.

    Article  PubMed  CAS  Google Scholar 

  33. Kassir N, Labbé L, Delaloye J, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. Br J Clin Pharmacol. 2014;77(6):1051–63.

    Article  CAS  PubMed  Google Scholar 

  34. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet. 2005;44(12):1317–28.

    Article  CAS  PubMed  Google Scholar 

  35. Kuypers D, Claes K, Evenepoel P, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids—a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43(11):741–62.

    Article  CAS  PubMed  Google Scholar 

  36. de Jonge H, Vanhove T, de Loor H, et al. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol. 2015;80(3):548–59.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Glowacki F, Lionet A, Buob D, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 2011;26(9):3046–50.

    Article  CAS  PubMed  Google Scholar 

  39. Barbarino J, Staatz C, Venkataramanan R, et al. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kurzawski M, Droździk M. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. Pharmacogenomics. 2013;14(9):1099–118.

    Article  CAS  PubMed  Google Scholar 

  41. Picard N, Marquet P. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol. 2011;7(6):731–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Dessilly G, Elens L, Panin N, et al. ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. PLoS One. 2014;9(3):e91555.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Monostory K, Toth K, Kiss A, et al. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. Br J Clin Pharmacol. 2015;80(6):1429–37.

    Article  CAS  PubMed  Google Scholar 

  44. Pulk R, Schlad D, Oetting W, et al. Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics. 2015;16(8):841–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Boivin A, Cardinal H, Barama A, et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug Metab Pharmacokinet. 2013;28(3):274–7.

    Article  CAS  PubMed  Google Scholar 

  46. Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008;30:143–50.

    Article  CAS  PubMed  Google Scholar 

  47. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721–6.

    CAS  PubMed  Google Scholar 

  48. Shuker N, Bouamar R, van Schaik RH, et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2015;. doi:10.1111/ajt.13691 (Epub 2015 Dec 29).

    Google Scholar 

  49. Holford N, Buclin T. Safe and effective variability—a criterion for dose individualization. Ther Drug Monit. 2012;34(5):565–8.

    Article  CAS  PubMed  Google Scholar 

  50. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876–85.

    Article  CAS  PubMed  Google Scholar 

  51. van Lent-Evers N, Mathot R, Geus W, et al. Impact of goal-orientated and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21(1):63–73.

    Article  PubMed  Google Scholar 

  52. Evans W, Relling MV, Rodman J, et al. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia. N Engl J Med. 1998;338(8):499–505.

    Article  CAS  PubMed  Google Scholar 

  53. Storset E, Asberg A, Skauby M, et al. Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients-a prospective, randomized study. Transplantation. 2015;99:2158–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Boots J, Van Duijnhoven E, Christiaans M, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol. 2002;13:221–7.

    CAS  PubMed  Google Scholar 

  55. Cosio F, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83(4):411–6.

    Article  PubMed  Google Scholar 

  56. Lemaitre F, Blanchet B, Latournerie M, et al. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells. Clin Biochem. 2015;48(6):406–11.

    Article  CAS  PubMed  Google Scholar 

  57. Barraclough K, Staatz C, Isbel N. Pharmacokinetic, pharmacogenetic and pharmacodynamic monitoring of tacrolimus, mycophenolate and oral corticosteroids in adult kidney transplantation. In: Lim WH, editor. The complex evolution of kidney transplantation: pre-transplant donor and recipient assessment, transplant surgery, immunosuppression, high risk transplants and management of post transplant complications. Organ Transplant Research Horizons; Renal and Urologic Disorders. New York: Nova Science Publisher; 2014. p. 185–261.

  58. Fuchs A, Csajka C, Thoma Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52(1):9–22.

    Article  CAS  PubMed  Google Scholar 

  59. Pharmacology LUHLo. ImmunoSuppressants Bayesian dose Adjustment (ISBA). Limoges; 2005. https://pharmaco.chu-limoges.fr. Accessed 4 Apr 2016.

  60. Barraclough K, Isbel NM, Kirkpatrick CM, et al. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol. 2011;71(2):207–23.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48(12):805–16.

    Article  CAS  PubMed  Google Scholar 

  62. Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet. 2010;49(10):683–92.

    Article  CAS  PubMed  Google Scholar 

  63. Antignac M, Barrou B, Farinotti R, et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64(6):750–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Scholten E, Cremers S, Schoemaker R, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440–7.

    Article  CAS  PubMed  Google Scholar 

  65. Staatz C, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72(6):660–9.

    Article  CAS  PubMed  Google Scholar 

  66. Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit. 2010;32(2):129–35.

    CAS  PubMed  Google Scholar 

  67. Press R, Ploeger B, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187–97.

    Article  CAS  PubMed  Google Scholar 

  68. Saint-Marcoux F, Debord J, Parant F, et al. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. Ther Drug Monit. 2011;33:171–7.

    Article  CAS  PubMed  Google Scholar 

  69. Velickovic-Radovanovic R, Catic-Djordjevic A, Milovanovic J, et al. Population pharmacokinetics of tacrolimus in kidney transplant patients. Int J Clin Pharmacol Ther. 2010;48(6):375–82.

    Article  CAS  PubMed  Google Scholar 

  70. Han N, Yun HY, Hong JY, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53–63.

    Article  CAS  PubMed  Google Scholar 

  71. Ogasawara K, Chitnis S, Gohh R, et al. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52(9):751–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Zuo X, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom. 2013;23(5):251–61.

    Article  CAS  Google Scholar 

  73. Andreu F, Colom H, Grinyo J, et al. Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit. 2015;37(2):246–55.

    Article  CAS  PubMed  Google Scholar 

  74. Bergmann T, Hennig S, Barraclough K, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36:62–70.

    CAS  PubMed  Google Scholar 

  75. Asberg A, Midtvedt K, van Guilder M, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transplant Int. 2013;26(12):1198–207.

    Article  CAS  Google Scholar 

  76. Golubovic B, Vucicevic K, Radivojevic D, et al. Total plasma protein effect on tacrolimus elimination in kidney transplant patients–population pharmacokinetic approach. Eur J Pharm Sci. 2014;52:34–40.

    Article  CAS  PubMed  Google Scholar 

  77. Han N, Ha S, Yun H, et al. Population pharmacokinetic–pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol. 2014;114:400–6.

    Article  CAS  PubMed  Google Scholar 

  78. Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609–18.

    Article  CAS  PubMed  Google Scholar 

  79. Zhao W, Fakhoury M, Baudouin V, et al. Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(2):189–95.

    Article  CAS  PubMed  Google Scholar 

  80. Jacobo-Cabral C, Garcia-Roca P, Romero-Tejeda EM, et al. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. Br J Clin Pharmacol. 2015;80(4):630–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Staatz C, Willis C, Taylor PJ, et al. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9(2):130–7.

    Article  PubMed  Google Scholar 

  82. Macchi-Andanson M, Charpiat B, Jelliffe RW, et al. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit. 2001;23(2):129–33.

    Article  CAS  PubMed  Google Scholar 

  83. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6–7):479–84.

    CAS  PubMed  Google Scholar 

  84. Fukudo M, Yano I, Fukatsu S, et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 2003;42(13):1161.

    Article  CAS  PubMed  Google Scholar 

  85. Zahir H, McLachlan A, Nelson A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit. 2005;27:422–30.

    Article  CAS  PubMed  Google Scholar 

  86. Li D, Lu W, Zhua J, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007;32:505–15.

    Article  CAS  PubMed  Google Scholar 

  87. Blanchet B, Duvoux C, Costentin C, et al. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit. 2008;30:412–8.

    CAS  PubMed  Google Scholar 

  88. Zhang X, Wang Z, Fan J, et al. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. Ther Drug Monit. 2012;34:126–33.

    Article  PubMed  CAS  Google Scholar 

  89. Oteo I, Lukas JC, Leal N, et al. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol. 2013;69(1):65–74.

    Article  CAS  PubMed  Google Scholar 

  90. Valdivieso N, Oteo I, Valdivieso A, et al. Tacrolimus dose individualization in “de novo” patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. Int J Clin Pharmacol Ther. 2013;51(7):606–14.

    Article  CAS  PubMed  Google Scholar 

  91. Sam W, Tham L, Holmes M, et al. Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet. 2006;45(1):59–75.

    Article  CAS  PubMed  Google Scholar 

  92. Zhu L, Wang H, Sun X, et al. The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients. J Pharm. 2014;2014:713650. doi:10.1155/2014/713650

    Google Scholar 

  93. Moes DJ, van der Bent SA, Swen JJ, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016;72(2):163–74.

    Article  CAS  PubMed  Google Scholar 

  94. Lu YX, Su QH, Wu KH, et al. A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacol Sin. 2015;36(2):281–8.

    Article  CAS  PubMed  Google Scholar 

  95. Wallin J, Bergstrand M, Wilczek HE, et al. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit. 2011;33(6):663–72.

    Article  CAS  PubMed  Google Scholar 

  96. Staatz C, Taylor P, Lynch S, et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation. 2001;72(6):1051–61.

    Article  Google Scholar 

  97. Sam W, Aw M, Quak H, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol. 2000;50:531–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Sanchez M, Manzanares C, Santos-Buelga D, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet. 2001;40(1):63–71.

    Article  CAS  Google Scholar 

  99. Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc. 1995;27(1):1108–10.

    CAS  PubMed  Google Scholar 

  100. Guy-Viterbo V, Scohy A, Verbeeck RK, et al. Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol. 2013;69(8):1533–42.

    Article  CAS  PubMed  Google Scholar 

  101. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006;80(4):331–45.

    Article  CAS  PubMed  Google Scholar 

  102. Guy-Viterbo V, Baudet H, Elens L, et al. Influence of donor–recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics. 2014;15(9):1207–21.

    Article  CAS  PubMed  Google Scholar 

  103. Musuamba F, Guy-Viterbo V, Reding R, et al. Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. Ther Drug Monit. 2014;36(1):54–61.

    CAS  PubMed  Google Scholar 

  104. Yang J, Liao SS, Zhu LQ, et al. Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther. 2015;53(1):75–83.

    Article  CAS  PubMed  Google Scholar 

  105. Monchaud C, de Winter BC, Knoop C, et al. Population pharmacokinetic modelling and design of a bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet. 2012;51(3):175–86.

    Article  CAS  PubMed  Google Scholar 

  106. Op den Buijsch R, van de Plas A, Stolk L, et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol. 2007;63(11):1039–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Zhao W, Fakhoury M, Baudouin V, et al. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients. Ther Drug Monit. 2011;33(6):681–7.

    Article  CAS  PubMed  Google Scholar 

  108. Zhao W, Maisin A, Baudouin V, et al. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. Eur J Clin Pharmacol. 2013;69(5):1181–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, The University of Queensland, Brisbane, QLD, Australia

    Emily Brooks & Nicole M. Isbel

  2. School of Pharmacy, The University of Queensland, Brisbane, QLD, 4102, Australia

    Susan E. Tett & Christine E. Staatz

  3. Department of Nephrology, The Princess Alexandra Hospital, Brisbane, QLD, Australia

    Nicole M. Isbel

Authors
  1. Emily Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan E. Tett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole M. Isbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine E. Staatz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan E. Tett.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this review. Dr Brooks was a student; Dr Tett, Dr Staatz and Dr Isbel receive salaries from university/hospital sources.

Conflict of interest

Dr Brooks, Dr Tett, Dr Isbel and Dr Staatz have no conflicts of interest that are relevant to the content of this review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brooks, E., Tett, S.E., Isbel, N.M. et al. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?. Clin Pharmacokinet 55, 1295–1335 (2016). https://doi.org/10.1007/s40262-016-0396-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-016-0396-1

Keywords

Search

Navigation